‘It shouldn’t be this bad’: Pediatricians scramble for RSV shots amid shortage

Dr. Monique Soileau-Burke has seen a surge in sick babies and worried parents bringing their children to her for treatment of the respiratory syncytial virus (RSV) in recent weeks. RSV is a dangerous contagion that spreads in colder months, particularly affecting the very young and older adults.

Last year saw a significant spike in RSV-related hospitalizations, leading to overwhelming demand for treatment. This year, despite a slower start, RSV is still spreading quickly and infecting more children than in a typical winter.

A new immunization drug, nirsevimab, was approved earlier this year, providing hope for protection against RSV. However, the drug is in short supply and facing high demand. This has led to rationing of doses, leaving many infants at risk.

Pediatricians are concerned about the shortage and are urging pregnant people to get vaccinated against RSV. This would pass passive antibodies on to their babies, providing protection without the need for a separate immunization.

Amidst the dwindling supply of nirsevimab, an alternative drug, palivizumab, is available, but it is more expensive and requires monthly doses throughout the respiratory season.

The CDC has announced plans to distribute additional doses of nirsevimab, but pediatricians are still concerned about the ongoing shortage and the impact it could have on infants.

With RSV posing a significant health risk to infants and seniors, the shortage of nirsevimab is causing widespread concern among medical professionals. Dr. Natalie Davis, Chief of Neonatology at the University of Maryland Children’s Hospital, expressed hope for increased availability in future years and relief that the alternative drug, palivizumab, is still an option for protection.

The ongoing shortage of nirsevimab highlights the importance of access to critical vaccines for vulnerable populations, such as infants. It also raises concerns about the capacity to meet the demand for essential immunization drugs, and the need for comprehensive solutions to address such shortages in the future.